Related Experiment Video

Updated: Feb 7, 2026

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.3K

Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind,

Teemu J Murtola1, Heimo Syvälä2, Teemu Tolonen3

  • 1Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland; Department of Urology, Tampere University Hospital, Tampere, Finland.

European Urology
|July 23, 2018
PubMed

Insights

Atorvastatin did not significantly reduce prostate cancer proliferation (Ki-67) or PSA overall. However, longer atorvastatin use (≥28 days) showed potential benefits in exploratory analyses for high-grade cases.

Area of Science:

  • Oncology
  • Pharmacology
  • Urology

Background:

  • Prostate cancer is a significant health concern.
  • Statins, like atorvastatin, are widely used for cholesterol management.
  • The potential anti-cancer effects of statins warrant investigation.

Purpose of the Study:

  • To evaluate the efficacy of atorvastatin in reducing prostate cancer proliferation and PSA levels.
  • To assess the impact of atorvastatin on intraprostatic inflammation.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial involving 160 men with prostate cancer.
  • Participants received 80mg atorvastatin or placebo daily before radical prostatectomy.
  • Tumor proliferation (Ki-67) and serum PSA levels were measured.

Main Results:

  • Overall, atorvastatin did not significantly alter Ki-67 or PSA levels compared to placebo.
  • Subgroup analysis indicated a trend towards reduced Ki-67 after ≥28 days of atorvastatin (p=0.056).
  • High-grade prostate cancer patients showed a significant reduction in PSA with atorvastatin (p=0.024).

Conclusions:

  • Atorvastatin demonstrated no significant overall benefit in reducing prostate cancer proliferation or PSA.
  • Exploratory analyses suggest potential benefits with longer exposure (≥28 days), particularly in high-grade cases.
  • Further research is needed to confirm these preliminary findings.
Keywords:
AtorvastatinClinical trialInflammationKi-67Prostate cancerProstate-specific antigen

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.2K
How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants08:50

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

Published on: December 14, 2014

9.7K

Related Concept Videos

The Placebo Effect01:54

The Placebo Effect

The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.9K
Blind Procedures02:07

Blind Procedures

Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
13.6K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.6K
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
4.0K